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Corticosterone and 11-dehydrocorticosterone stimulate Na,K-
ATPase gene expression in vascular smooth muscle cells.
Background. In mineralocorticoid target tissues such as kidney
and colon, the enzyme 11b-hydroxysteroid dehydrogenase
(11bOHSD) catalizes the reversible conversion of corticosterone
(CS) to inactive 11-dehydrocorticosterone (DHCS) in rats, and
cortisol to inactive cortisone in humans. This enzyme is also
expressed in vascular smooth muscle cells (VSMC).
Methods. In cultured VSMC from rat thoracic aortae, we
examined the effects of CS and DHCS on Na,K-ATPase a1- and
b1-mRNA accumulation by Northern blot analysis, on a1- and
b1-subunit protein accumulation by Western blot analysis, and on
Na,K-ATPase activity by the coupled assay method.
Results. In VSMC, CS and DHCS (1026 M) increased a1-
mRNA level 2.6- and 2.5-fold at 48 hours and b1-mRNA level 9.2-
and 9.1-fold at 12 hours, respectively. The RNA transcription
inhibitor (actinomycin D) abolished both CS- and DHCS-medi-
ated a1- and b1-mRNA induction. The glucocorticoid receptor
antagonist (RU38486) and the mineralocorticoid receptor antag-
onists (ZK91587) inhibited both CS- and DHCS-mediated a1-
and b1-mRNA induction. The 11bOHSD inhibitor (carbenox-
olone) inhibited DHCS-mediated a1- and b1-mRNA induction,
whereas it caused no effect on CS-mediated a1- or b1-mRNA
induction. The addition of CS or DHCS to VSMC significantly
increased a1- and b1-subunit protein levels and Na,K-ATPase
activity. When adrenalectomized rats were treated with CS or
DHCS for 12 hours, aorta a1- and b1-mRNA levels increased 3.0-
and 8.7-fold or 3.4- and 8.4-fold, respectively.
Conclusions. In VSMC, both CS and DHCS stimulate Na,K-
ATPase a1- and b1-mRNA accumulation, a1- and b1-subunit
protein accumulation, and Na,K-ATPase activity. The CS-medi-
ated a1- and b1-mRNA induction occurs independently of
11bOHSD, whereas the DHCS-mediated a1- and b1-mRNA
induction occurs through 11bOHSD-dependent mechanisms, pos-
sibly via conversion of inactive DHCS into active CS.
The Na,K-ATPase (Na pump) is a heterodimeric trans-
membrane protein found in all mammalian cells. This
protein maintains intracellular ion composition by trans-
porting Na and K against their concentration gradients
across the cell membrane, and plays a central role in the
regulation of membrane potential, cell ion content, and cell
volume in various kinds of cells, including vascular smooth
muscle cells (VSMC) [1]. Structurally, the enzyme is com-
posed of at least two subunits: a large catalytic a-subunit
and a smaller glycosilated b-subunit [reviewed in 2]. The
a-subunit contains an intracellular ATP binding site, a
phosphorylation site, and an extracellular binding site for
cardiac glycoside, that is, ouabain. On the other hand, the
b-subunit is thought to be involved in subunit assembly and
in functional maturation. The two subunits are encoded by
multigene families, and appear to be differentially ex-
pressed among tissues and during development [3, 4]. In
rats, cDNAs encoding three a-subunit isoforms (a1, a2,
a3) have been cloned and sequenced [3–5]. Three b-sub-
unit isoforms (b1, b2, b3) have also been cloned and
sequenced in rats [4, 6–8]. In rat VSMC the predominant
isoforms of Na,K-ATPase are the a1- and b1-isoforms [9,
10].
Adrenal corticosteroids such as glucocorticoids (such as,
dexamethasone) and mineralocorticoids (such as, aldoste-
rone), which have well-characterized effects on renal [11–
15] and colonic [16] Na and K transport, are potent
regulators of Na,K-ATPase activity in these tissues. These
corticosteroid effects are mediated via two intracellular
receptors: type I mineralocorticoid and type II glucocorti-
coid receptors (MR and GR, respectively) [16, 17]. In
VSMC, corticosteroid binding sites with the characteristics
of both MR and GR have also been reported [18, 19].
Recently Muto et al [20] reported that both dexamethasone
and aldosterone induce Na,K-ATPase a1- and b1-mRNA
accumulation in cultured VSMC in a time- and dose-
dependent manner, but the mechanisms of these two
corticosteroids differ strikingly. Dexamethasone-induced
b1-mRNA up-regulation occurs only through GR, whereas
aldosterone-induced b1-mRNA up-regulation occurs through
both MR and GR. However, the mechanisms for dexa-
methasone- or aldosterone-induced a1-mRNA upregula-
tion are not fully understood. A further consideration in
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the analysis of the corticosteroid effects is the activity of
11b-hydroxysteroid dehydrogenase (11bOHSD), which
catalyzes the reversible conversion of corticosterone (CS)
to inactive 11-dehydrocorticosterone (DHCS) in rats, or
cortisol to inactive cortisone in humans [reviewed in 21].
This enzyme is expressed at high levels in mineralocorticoid
target tissues (such as kidney and colon), and can be
regarded as a “moat” protecting the nonselective MR from
cortisol (or CS) access [21]. A deficiency of 11bOHSD,
either congenital [22] or when the enzyme is inhibited by
licorice [23] or carbenoxolone [24], results in cortisol–but
not aldosterone–acting as a potent mineralocorticoid on
the kidney and colon. In VSMC, the co-localization of
11bOHSD and corticosteroid receptors has also been
reported [25, 26]. This raises the possibility that in rat
VSMC such as mineralocorticoid target tissues, Na,K-
ATPase gene expression may be regulated by CS rather
than by DHCS, via 11bOHSD. However, CS and/or DHCS
effects on Na,K-ATPase gene expression in VSMC are not
yet understood.
In our previous report [20], we used a synthetic glucocor-
ticoid (dexamethasone) to demonstrate the mechanisms
whereby this glucocorticoid stimulates Na,K-ATPase b1-
mRNA expression in VSMC. However, Meyer and Nichols
[19] reported that in rat aortic cells, CS binds to both GR
and MR, whereas dexamethasone binds to only GR. Their
report raises the possibility that in vascular tissues, natu-
rally-occurring glucocorticoids may have different modes of
action from synthetic glucocorticoids. In the present study
we chose CS as a glucocorticoid because this steroid is the
natural, and possibly the sole, glucocorticoids in rats [27].
Therefore, the purpose of the present study was to
address the following issues: (1) whether CS or DHCS
stimulates Na,K-ATPase a1- and b1-mRNA accumulation,
a1- and b1-subunit protein accumulation, and Na,K-AT-
Pase activity in VSMC; (2) What the mechanisms are for
up-regulation of a1- and b1-mRNA induced by CS or
DHCS; and (3) How Na,K-ATPase gene expression in-
duced by CS or DHCS is modulated by 11bOHSD.
METHODS
Cell culture
Primary cultures of rat VSMC were isolated from tho-
racic aortae of male Sprague-Dawley rats (200 to 250 g) by
treatment with collagenase, as described previously [20].
The cells were cultured in Eagle’s minimal essential me-
dium (MEM) supplemented with 10% fetal bovine serum
(FBS), 26.1 mM NaHCO3, 100 U/ml penicillin, and 100
mg/ml streptomycin in a 5% CO2 incubator at 37°C. After
reaching confluence, VSMC were passaged through tryp-
sin/EDTA and seeded at a 1:3 ratio in 100-mm culture
dishes (Becton Dickinson, Rahway, NJ, USA). Experi-
ments were performed with VSMC that were grown to
confluence after 4 to 10 passages.
Animals
Male Sprague-Dawley rats weighing 200 to 250 g were
bilaterally adrenalectomized (ADX) with ether anesthesia
and then maintained with free access to food and to 0.9%
NaCl solution. After a period of 7 to 10 days, CS (1 mg/kg
body wt), DHCS (1 mg/kg body wt), or vehicle alone was
injected subcutaneously; both steroids were dissolved in
sesame oil. After 12 hours the animals were killed, and
aorta samples were frozen in liquid nitrogen before isola-
tion of total RNA.
Northern blot analysis
Total RNA was extracted from cultured VSMC or from
the aorta as described previously in our laboratory [20]. In
brief, confluent VSMC or the aorta were lysed using
ISOGENy (Nippon Gene, Tokyo, Japan), which contained
phenol and guanidine isothiocyanate. The lysate was ex-
tracted with chloroform/isopropanol. Total RNA was then
precipitated with 100% ethanol, and washed with 75%
ethanol, and dissolved in 25 ml of diethyl pyrocarbonate-
treated water. The RNA was quantitated by ultraviolet
absorbance at 260 nm. The RNA (20 mg) was fractionated
on 1% denaturing agarose-formaldehyde gels and capillary
blotted onto nylon membranes (Hybond N, Amersham,
Bucks, UK) in 20 3 standard saline citrate (SSC) (1 3 SSC
contains 0.15 M NaCl and 0.0015 M sodium citrate, pH 7.0.)
overnight. Filters were prehybridized for 30 minutes at
68°C before hybridization using Quick-Hyby (Stratagene,
La Jolla, CA, USA), a hybridization solution designed to
shorten hybridization time. Filters were then hybridized for
one hour at 68°C in the same solution with 106 cpm/ml of
[a-32P]dCTP random primer-labeled Na,K-ATPase a1-
and b1-cDNA probes from rats. The a1-cDNA probe
consisted of a 2.2 kb NcoI restriction fragment [28], and the
b1-cDNA probe consisted of a 0.9 kb PstI-SpeI restriction
fragment [29]. Filters were washed twice for 10 minutes at
room temperature in 2 3 SSC and 0.1% sodium dodecyl
sulfate (SDS) followed by a 10 minutes wash at 45°C in
0.1 3 SSC and 0.1% SDS. Autoradiography was performed
at 270°C and quantitated by densitometric scanning (Im-
age Analyzer TIF-64; Immunomedica, Tokyo, Japan). The
filter membranes were also hybridized with [g-32P]ATP-
labeled rat glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) oligonucleotide probe. The a1- and b1-mRNA
areas were standardized for each lane in the GAPDH area
to control for variability in RNA loading.
Western blot analysis
Confluent VSMC were incubated in serum-free MEM
for 48 hours, and were then treated with CS or DHCS
(1026 M) for the next 24 hours. They were washed three
times with ice-cold phosphate buffered saline (PBS),
scraped, and centrifuged at 1,600 3 g for three minutes at
4°C. The supernatant was removed, and cell pellets were
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stored at 270°C before use. Homogenization was per-
formed by sonication with Branson sonifier (Branson Ul-
trasonics Corporation, Danbury, CT, USA) at settings of 3
40% ducy cycle, 20 pulses in homogenization buffer (250
mM sucrose, 5 mM NaN3, 2 mM EGTA, 200 mM phenylmeth-
ylsulfonyl fluoride, 1 mM leupeptin, 1 mM pepstatin A, and
20 mM Hepes, pH 7.4). Homogenate extracts were centri-
fuged for three minutes at 1,600 3 g at 4°C to pellet
unbroken cells, and the resulting supernatant was collected
for use in immunoblotting. The protein content of the cells
was determined by the Bio-Rad protein assay kit (Bio-Rad
Laboratories Inc., Richmond, CA, USA), using bovine
serum albumin as the standard.
Homogenate protein (20 mg) was subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) on polyacryamide gels (9.0% for a1, and 10.5% for
b1), and then electrophoretically blotted onto nitrocellu-
lose membranes (Hybond-ECL; Amersham). Uniform
blotting across the gel was verified by Coomasie brilliant
blue staining of the post-blot gel. The transfer membranes
were incubated for one hour at room temperature with Tris
buffered saline-Tween 20 (TBS-Tween; 150 mM NaCl, 50
mM Tris/HCl, pH 7.5, 0.1% Tween 20) containing 5%
(wt/vol) skim milk, followed by a one hour incubation with
the desired antibody, that is, rabbit anti-rat Na,K-ATPase
a1- or b1-specific antibodies (Upstate Biotechnology Inc.,
Lake Placid, NY, USA). The antibodies were diluted in
TBS-Tween (1:200 for a1, or 1:1,000 for b1). After incu-
bation, the membranes were washed three times for 15
minutes each in TBS-Tween at room temperature, and
were then incubated for one hour with horseradish perox-
idase-conjugated donkey anti-rabbit immunoglobulin G
antibody (1:5,000 dilution; Amersham). The membranes
were again washed three times for 15 minutes each in
TBS-Tween at room temperature, and were then made
visible by fluorography with enhanced chemiluminescence
detection kit (Amersham). The results were quantitated by
densitometric scanning (Immunomedica), and expressed as
relative increase compared with control. The reliability of
the kit for quantitation of protein abundance was deter-
mined. We loaded 10, 20, and 40 mg cell homogenate and
resolved by SDS-PAGE. The densitometer scanned immu-
noblotting results of the above samples were plotted and
revealed a satisfactory linearity.
Measurement of Na,K-ATPase activity
Vascular smooth muscle cells (VSMC) were cultured
and grown in 60 mm culture dishes (Becton Dickinson).
Confluent VSMC were incubated in serum-free MEM for
48 hours. They were then exposed to MEM or MEM
treated with 1026 M CS or DHCS. After 24- or 48-hours of
incubation, they were rinsed three times with ice-cold PBS,
scraped, and centrifuged at 1,600 3 g for three minutes at
4°C. After the supernatant was aspirated, the cells were
hypotonically lysed in 1 mM Tris-HCl, pH 7.4, at 4°C,
followed by mechanical disruption by sonication with Bran-
son sonifier (Branson Ultrasonics Corporation) at settings
of three 40% duty cycle, 20 pulses. Homogenate extracts
were then centrifuged for three minutes at 1,600 3 g at 4°C
to pellet unbroken cells, and the resulting supernatant was
collected for use in Na,K-ATPase activity.
The ATPase assay couples the hydrolysis of adenosine
triphosphate (ATP) to adenosine 59-diphosphate (ADP) to
the oxidation of NADH. As previously described [30–32],
we used NH4
1 in place of K1 as an incubation medium for
the measurement of ATPase activity, since both pyruvate
kinase and lactate dehydrogenase contain a considerable
amount of NH4
1, which, like K1, activates the ATPase [33,
34]. Cell homogenates prepared above were divided into
two parts that were incubated with or without 4 mM
ouabain at 37°C for 15 minutes in the following incubation
medium (in mM): 100 NaCl, 67 NH4Cl, 50 imidazole, 3.7
MgCl2, 1.1 Na2ATP, 0.8 phosphoenolpyruvate, 2.5 sodium
azide and 0.01 NADH, in addition to 3.2 U/ml pyruvate
kinase and 4.1 U/ml lactate dehydrogenase, pH 7.4. The
fluorescence was measured using a fluorometer (RF-5000;
Shimadzu Corporation, Kyoto, Japan) with excitation at
340 nm and emission at 460 nm. Na,K-ATPase activity was
equivalent to the activity measured without ouabain minus
the activity measured in the presence of ouabain, and
expressed as mmol/mg protein/hr. The protein content of
the cells was determined by the Bio-Rad protein assay kit
(Bio-Rad).
Chemicals
All chemicals were obtained from Sigma Chemical Co.
(St. Louis, MO, USA) unless noted. They are as follows:
MEM, penicillin, streptomycin, and FBS were from Flow
laboratories (Irvine, Scotland, UK); [a-32P]dCTP and
[g-32P]ATP were from Amersham; rat GAPDH probe
was from Oncogene Science (Uniondale, NY, USA);
rabbit anti-rat Na,K-ATPase a1- and b1-subunit specific
polyclonal antibodies were from Upstate Biotechnology
Inc.; ZK91587 was from New England Nuclear (Boston,
MA, USA); and Na2ATP, NADH, pyruvate kinase,
lactate dehydrogenase, and phosphoenolpyruvate were
from Boehringer Mannheim (Mannheim, Germany).
RU38486 was a generous gift from Roussel Uclaf (Ro-
mainville, France).
Statistical analysis
Values are expressed as means 6 SE. Comparisons were
performed by nonpaired Student’s t-test, Mann-Whitney’s
U-test, or one-way analysis of variance in combination with
Schefe’s multiple comparison test, as needed. P values less
than 0.05 were considered significant.
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RESULTS
Effects of CS or DHCS on a1- and b1-mRNA
accumulation in VSMC
We first examined the effects of CS or its metabolites,
DHCS or 21-desoxycortisone (DC), on Na,K-ATPase gene
expression in VSMC. VSMC were placed in serum-free
MEM for 48 hours prior to the addition of the steroid
hormones, and were then exposed to either hormone at
1026 M for another 12 hours. As shown in Figure 1, the
a1-cDNA probe hybridized to a single band estimated at
3.7 kb, which is in close agreement with the size of
a1-mRNA in various rat tissues. In contrast, the b1-cDNA
probe hybridized to a broad band ranging from 1.4 to 2.9
kb. Both CS and DHCS increased a1- and b1-mRNA
accumulation 2.1- and 9.0-fold and 2.3- and 8.6-fold, re-
spectively. In sharp contrast, another 11-dehydro derivative
DC had no effect on a1- or b1-mRNA levels. Therefore,
the effects of DHCS on Na,K-ATPase gene expression
appeared to be relatively specific. We performed the next
series of experiments to determine the time courses of
changes in mRNA levels induced by CS or DHCS. Repre-
sentative Northern blot analyses of a1- and b1-mRNA
accumulation in CS-treated VSMC are shown in Figure 2A,
and quantitations of each mRNA amount are summarized
in Figure 2B. Control MEM caused no effect at any time.
Treatment with CS gradually increased a1-mRNA levels,
with a maximum 2.6-fold elevation at 48 hours. When
VSMC were exposed to CS, b1-mRNA levels rapidly
increased to 4.8 times the control level by as early as three
hours, with a maximum 9.2-fold increase at 12 hours, and
then gradually decreased to 4.3 times the control level at 48
hours. Similar results were also observed in DHCS-treated
Fig. 1. Effects of 12-hour incubation with corticosterone (CS), 11-dehydrocorticosterone (DHCS), or 21-desoxycortisone (DC) on Na,K-ATPase a1-
and b1-mRNA accumulation in vascular smooth muscle cells (VSMC). (A) Northern blot analyses. (B) Quantitations of the Northern blot. Data are
means 6 SE of 3 separate experiments, expressed as a relative increase in mRNA expression compared with control samples. *P , 0.005, **P , 0.001
compared to control.
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VSMC. Representative Northern blot analyses are shown
in Figure 3A, and quantitations of each mRNA amount are
summarized in Figure 3B. Control MEM showed relatively
constant levels of both a1- and b1-mRNA throughout the
48-hour period. Treatment with DHCS gradually increased
a1-mRNA levels, with a maximum 2.5-fold elevation at 48
hours. Upon the addition of DHCS to VSMC, b1-mRNA
levels rapidly increased to 3.3 times the control level by as
early as three hours, with a maximum 9.1-fold increase at 12
hours, and then gradually decreased to 4.9 times the control
level at 48 hours.
Dose dependency
We next examined the dose-dependent effects of CS or
DHCS on a1- and b1-mRNA accumulation. VSMC were
placed in serum-free MEM for 48 hours prior to the
addition of the steroid hormones, and were then exposed to
either hormone for 12 hours at various concentrations.
Fig. 2. Time course of Na,K-ATPase a1- and
b1-mRNA accumulation by CS in VSMC. (A)
Northern blot analyses. (B) Quantitations of
the Northern blot. Abundance of mRNA is
expressed as units of densitometry relative to
time 0, and each data point is means 6 SE of
five separate experiments. *P , 0.05, #P ,
0.01, †P , 0.001 compared to control.
Symbols are: (f) control; (l) CS.
Muto et al: Na,K-ATPase gene expression by glucocorticoids496
Representative Northern blot analyses are shown in Figure
4A, and quantitations of these experiments are given in
Figure 4B. Both CS and DHCS increased a1- and b1-
mRNA levels in a dose-dependent manner; significant
effects of CS or DHCS on a1- and b1-mRNA levels
occurred at more than 1028 M, and maximal effects on a1-
and b1-mRNA levels occurred at 1026 M. In rats, plasma
concentration of CS is in the range of 1027 to 1026 M [35].
Therefore, the above findings indicate that CS at physio-
logical concentrations increases a1- and b1-mRNA levels.
Effects of actinomycin D on CS- and DHCS-mediated
a1- and b1-mRNA induction
To determine whether CS and DHCS affect a1- and
b1-mRNA accumulation by increasing the rate of synthesis
or decreasing the rate of degradation, we examined the
Fig. 3. Time course of Na,K-ATPase a1- and
b1-mRNA accumulation by DHCS in VSMC.
(A) Northern blot analyses. (B) Quantitations
of the Northern blot. Abundance of mRNA is
expressed as units of densitometry relative to
time 0, each point is means 6 SE of five
separate experiments. *P , 0.01, #P , 0.005,
†P , 0.001 compared to control. Symbols are:
(f) control; (l) DHCS.
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effect of the mRNA transcription inhibitor actinomycin
D. For this experiment, VSMC were preincubated with
actinomycin D (5 mg/ml) for one hour prior to the
addition of CS or DHCS (1026 M), and then exposed to
either hormone for a 12-hour period. Representative
Northern blots are shown in Figure 5A, and quantita-
tions of the Northern blots are summarized in Figure 5B.
Actinomycin D alone had no effect on a1- or b1-mRNA
levels. CS or DHCS alone increased a1-mRNA levels
2.1- to 2.3-fold, and b1-mRNA levels increased 7.9- to
8.3-fold, respectively. Actinomycin D completely abol-
ished the stimulatory effect of CS and DHCS on a1- and
b1-mRNA levels.
Effects of RU38486 or ZK91587 on CS- and DHCS-
mediated a1- and b1-mRNA induction
To examine whether CS- and DHCS-mediated induction
of a1- and b1-mRNA occurs via GR and/or MR, VSMC
Fig. 4. Dose-dependent effects of CS and DHCS on Na,K-ATPase a1- and b1-mRNA accumulation in VSMC. (A) Northern blot analyses for CS- or
DHCS-supplemented media. (B) Quantitations of the Northern blot. Abundance of mRNA is expressed as units of densitometry relative to control, and
data are means 6 SE of 4 separate experiments. *P , 0.05, #P , 0.01,†P , 0.001 compared to control.
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were placed in serum-free MEM for 48 hours, and were
then exposed to the GR antagonist RU38486 (1025 M) or
the MR antagonist ZK91587 (1025 M), plus either CS or
DHCS (1026 M) for 12 hours. Representative Northern blot
analyses are shown in Figures 6A (for RU38486-treated
VSMC) and 7A (for ZK91587-treated VSMC), and quan-
titations of the Northern blots are summarized in Figures
6B (for RU38486-treated VSMC) and 7B (for ZK91587-
treated VSMC). RU38486 or ZK91587 alone caused no
effect on a1- or b1-mRNA accumulation. CS or DHCS
alone elevated a1- and b1-mRNA levels 2.1- to 2.5-fold and
7.9- to 8.6-fold, respectively. The addition of RU38486
Fig. 5. Effects of a transcription inhibitor,
actinomycin D (ACD), on CS- and DHCS-
induced upregulation of a1- and b1-mRNA
accumulation in VSMC. (A) Northern blot
analyses in VSMC exposed to control MEM,
CS- or DHCS-supplemented MEM in the
absence or presence of 5 mg/ml ACD. (B)
Quantitations of the Northern blot for CS- or
DHCS-supplemented media. Data are
means 6 SE of 4 separate experiments,
expressed as a relative increase in mRNA
expression compared with control samples.
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completely inhibited the CS- and DHCS-mediated a1- and
b1-mRNA induction. ZK91587 partially inhibited the CS-
and DHCS-mediated a1- and b1- mRNA induction.
Effects of carbenoxolone on CS- and DHCS-mediated a1-
and b1-mRNA induction
To examine whether CS- and DHCS-mediated a1- and
b1-mRNA induction is mediated by 11bOHSD, we used
an 11bOHSD inhibitor, carbenoxolone, which is a syn-
thetic licorice derivative. It has been reported that
carbenoxolone at 1026 M inhibited 11bOHSD activity in
VSMC from rat aorta [36]. In addition, carbenoxolone in
the range of 5 3 1026 to 1025 M inhibited 11bOHSD
activity in fetal kidney 293 cells stably transfected with
human 11bOHSD [37]. Therefore, we used 1025 M
carbenoxolone in the present study. For this experiment,
VSMC were placed in serum-free MEM for 48 hours,
Fig. 6. Effects of the GR antagonist,
RU38486 (RU), on CS- and DHCS-induced
up-regulation of a1- and b1-mRNA in VSMC.
(A) Northern blot analyses in VSMC exposed
to control MEM, CS- or DHCS-supplemented
MEM in the absence or presence of 1025 M
RU. (B) Quantitations of the Northern blot.
Data are expressed as a relative increase in
mRNA expression compared with control
samples. The number of experiments done on
CS- or DHCS-treated VSMC is 4.
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and were then treated with carbenoxolone (1025 M), plus
either CS or DHCS (1026 M) for 12 hours. Representa-
tive Northern blot analyses are shown in Figure 8A, and
quantitations of these experiments are summarized in
Figure 8B. Carbenoxolone alone had no effect on a1- or
b1-mRNA levels. CS or DHCS alone increased a1- and
b1- mRNA level 2.1- to 2.2-fold and 8.2- to 8.3-fold,
respectively. Treatment with carbenoxolone completely
inhibited the DHCS-mediated a1- and b1- mRNA in-
duction, whereas it caused no effect on the CS-mediated
a1- or b1-mRNA induction.
Effects of CS or DHCS on Na,K-ATPase a1- and b1-
subunit protein accumulation
We next examined whether CS or DHCS (1026 M) stimu-
late a1- and b1-subunit protein accumulation in VSMC.
Representative Western blot analyses are shown in Figure 9A,
Fig. 7. Effects of the MR antagonist, ZK91587
(ZK), on CS- and DHCS-induced up-
regulation of a1- and b1-mRNA in VSMC. (A)
Northern blot analyses in VSMC exposed to
control MEM, CS- or DHCS-supplemented
MEM in the absence or presence of 1025 M
ZK. (B) Quantitations of the Northern blot.
Data are expressed as a relative increase in
mRNA expression compared with control
samples. The number of experiments done on
CS- or DHCS-treated VSMC is 5.
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and quantitations of these experiments are summarized in
Figure 9B. When VSMC were treated with CS for 24 hours,
a1- and b1-subunit protein levels increased 2.2- and 2.0-fold,
respectively. Similarly, the addition of DHCS to VSMC for 24
hours increased a1- and b1-subunit protein levels 2.3- and
2.2-fold, respectively.
Effects of CS or DHCS on Na,K-ATPase activity
We next examined whether CS or DHCS (1026 M)
stimulate Na,K-ATPase activity in VSMC, and the results
are shown in Figure 10. When VSMC were treated with CS
for 24 or 48 hours, Na,K-ATPase activity increased 1.6- and
Fig. 8. Effects of the 11b-hydroxysteroid
dehydrogenase inhibitor, carbenoxolone (CBX),
on CS- and DHCS-induced up-regulation of
a1- and b1-mRNA in VSMC. (A) Northern
blot analyses in VSMC exposed to control
MEM, CS- or DHCS-supplemented MEM in
the absence or presence of 1025 M CBX. (B)
Quantitations of the Northern blot. Data are
expressed as a relative increase in mRNA
expression compared with control samples. The
number of experiments done on CS- or DHCS-
treated VSMC is 5 and 6, respectively.
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2.0-fold, respectively. Similarly, the addition of DHCS to
VSMC for 24 or 48 hours increased Na,K-ATPase activity
1.6- and 1.9-fold, respectively.
Effects of CS or DHCS on a1- and b1-mRNA
accumulation in rat aortae
Finally, we examined whether the CS- and DHCS-
mediated a1- and b1-mRNA induction observed in cul-
tured VSMC is actually found in rat aortae in vivo. There-
fore, bilaterally ADX rats were treated with CS, DHCS, or
vehicle alone for 12 hours, and total RNA isolated from
each aorta was assayed for a1- and b1-mRNA levels.
Representative Northern blot analyses are shown in Figure
11A, and quantitations of these experiments are summa-
rized in Figure 11B. When ADX rats were treated with CS,
aorta a1- and b1-mRNA levels increased 3.0- and 8.7-fold,
respectively. Similarly, administration of DHCS to ADX
rats increased aorta a1- and b1-mRNA levels 3.4- and
8.4-fold, respectively.
DISCUSSION
The present study was designed to determine the effects
of CS and DHCS on Na,K-ATPase gene expression in
cultured VSMC and rat aortae. This study demonstrates
that both CS and DHCS stimulate Na,K-ATPase a1- and
b1-mRNA accumulation, a1- and b1-subunit protein accu-
mulation, and Na,K-ATPase activity. We also found that
the CS- and DHCS-mediated a1- and b1-mRNA induction
Fig. 9. Effects of CS or DHCS on Na,K-ATPase a1- and b1-subunit protein accumulation. VSMC were exposed to CS or DHCS (1026 M) for 24 hours.
(A) Western blot analyses. (B) Quantitations of the Western blot. Abundance of each subunit protein is expressed as units of densitometry relative to
control. Data are means 6 SE of 7 separate experiments. *P , 0.001 compared with control. Symbols are: (M) control; (f) CS; (o) DHCS.
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occurs mainly due to increased mRNA production, and
that the CS- and DHCS-mediated a1- and b1-mRNA
induction occurs through both GR and MR. Furthermore,
the CS-mediated a1- and b1-mRNA induction occurs
independently of 11bOHSD, whereas the DHCS-mediated
a1- and b1-mRNA induction occurs through 11bOHSD-
dependent mechanisms. Administration of CS or DHCS to
ADX rats also stimulated a1- and b1-mRNA accumulation
in aorta.
In the present study we used multipassed cultured
VSMC. Although many of the characteristics of in situ
VSMC are lost in the subculturing process [38], the re-
sponse of Na,K-ATPase a1- and b1-mRNA levels to CS or
to DHCS in the cultured VSMC was similar to that seen in
the intact aorta (Figs. 1 and 11). Therefore, cultured
VSMC used in the present study could remain a good
model of in situ VSMC.
Up-regulation of Na,K-ATPase involves either coordi-
nate or noncoordinate changes in a and b subunit mRNA
with respect to time and/or magnitude. In this study CS and
DHCS increased both a1- and b1-mRNA accumulation
noncoordinately with respect to both time and magnitude.
A maximum increase in b1-mRNA in CS- or DHCS-
treated VSMC occurred at early time points, whereas that
of a1-mRNA occurred later. b1-mRNA levels in CS- or
DHCS-treated VSMC were much greater than a1-mRNA
levels. The Na,K-ATPase is thought to assemble and
function as an ab heterodimer. Thus, one possible expla-
nation for the disproportionate amounts of b1-mRNA is
that b1-mRNA is translated less efficiently than a1-mRNA.
Alternatively, the respective messages might be translated
with equal efficiency, but substantial amounts of b1-subunit
protein fail to assemble with the a1-subunit protein, and
are rapidly degraded. Similar noncordinate changes in a1-
and b1-mRNA have been reported in dexamethasone- or
aldosterone-treated VSMC [20]. This noncoordinate regu-
latory pattern has also been described in other cell systems.
In cultured rat mesangial cells, T3 stimulates a1-mRNA
levels faster than b1-mRNA levels [39]. In a rat liver cell
line, dexamethasone induces a much greater increase in
b1-mRNA expression than in a1-mRNA expression [40].
In A6 kidney cells, aldosterone induces a greater level of
b1-mRNA expression than of a1-mRNA expression [26].
Therefore, expression of Na,K-ATPase a- and b-subunit
genes may be regulated by different mechanisms depending
on cell type and stimuli. However, it is still unclear which
mechanisms give rise to these variations in patterns of
subunit expression.
Actinomycin D blocks DNA transcription and mRNA
synthesis by binding to the guanosine residues. Actinomy-
cin D can be used to investigate mRNA turnover, because
it does not markedly affect post-transcriptional steps that
lead to mRNA degradation [41]. In the presence of actino-
mycin D, CS or DHCS did not show an appreciable effect
on either a1- or b1-mRNA accumulation. Therfore, the
up-regulation of a1- and b1-mRNA observed in CS- and
DHCS-treated VSMC occurs mainly due to an increase in
mRNA synthesis in either the transcription or the RNA
processing steps, rather than due to a decrease in the
mRNA degradation rate.
To evaluate the extent to which CS may act through GR
and/or MR, we used specific antagonists of the respective
receptors. As shown in Figure 6, the GR antagonist,
RU38486, at 1025 M completely inhibited the CS-induced
a1- and b1-mRNA up-regulation. These findings indicate
that the CS-induced a1- and b1-mRNA up-regulation
occurs mainly through the GR. In addition, the CS-induced
a1- and b1-mRNA up-regulation may be mediated in part
by activation of the progesterone receptor, because
RU38486 is also a progesterone receptor antagonist. Re-
cently, the progesterone receptor has been reported in
VSMC [42]. It is also possible that the CS-induced a1- and
b1-mRNA up-regulation may partly occur through other
classes of corticosteroid receptors (such as, type III and IV
corticosteroid receptors). RU38486 has been reported to
inhibit type IV receptor in A6 cells [43]. A type III
intracellular corticosteroid-binding site has been identified
in VSMC, which has a higher affinity for CS than for
synthetic glucocorticoids [44]. As shown in Figure 7, the
MR antagonist, ZK91587, at an equivalent concentration
of RU38486 partially inhibited the CS-induced up-regula-
tion of a1- and b1-mRNA. These findings indicate that the
CS-induced a1- and b1-mRNA up-regulation occurs, at
least in part, through the MR. Thus, the CS-mediated a1-
and b1-mRNA induction occurs through both GR and MR.
These results are consistent with the report that the native
glucocorticoid CS binds to both MR and GR in rat aortic
cells [19]. In contrast to CS, the synthetic glucocorticoid
dexamethasone induces Na,K-ATPase b1-mRNA expres-
sion only through GR, as described previously by Muto et
Fig. 10. Effects of CS or DHCS on Na,K-ATPase activity. VSMC were
treated with CS or DHCS (1026 M) for 24 (N 5 8) or 48 hours (N 5 7).
Data are mean 6 SE. *P , 0.05, †P , 0.005, #P , 0.001 compared with
control. Symbols are: (M) control; (f) CS; (o) DHCS.
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al [20]. Therefore, in VSMC the effects of the native and
synthetic glucocorticoids on Na,K-ATPase gene expression
are similar, but their mechanisms are quite different. This
notion is also supported by the report that rat aortic cell
type I MR binds only to CS, whereas the type II GR binds
to both CS and dexamethasone [19]. Accordingly, CS has
both glucocorticoid and mineralocorticoid actions in rat
VSMC, as reported by Meyer and Nichols [19].
It has been reported that in cultured inner medullary
collecting duct cells from rat kidneys, the licorice derivative
glycyrrhetinic acid increased the stimulatory effect of CS on
short-circuit current [45]. The combined treatment with CS
and carbenoxolone is reported to induce a significant
increase in Na,K-ATPase activity in cortical collecting
ducts from ADX rat kidneys [46]. In addition, administra-
tion of carbenoxolone increased colonic Na,K-ATPase
a-mRNA levels in intact rats, but not in ADX rats [47].
These reports are consistent with the notion that inhibition
of CS metabolism via 11bOHSD produces an enhanced
ability to stimulate Na transport in these mineralocorticoid
target tissues. Therefore, the 11-dehydro derivative of CS,
DHCS, has been considered to be biologically inert in these
tissues: it does not induce a rise in Na transport and does
not appear to bind with high affinity to MR. In sharp
contrast to the kidney and colon, the present study dem-
onstrates that DHCS induces Na,K-ATPase gene expres-
sion in VSMC and in rat aortae. Effects of DHCS on
Na,K-ATPase gene expression with respect to time course,
dose dependency, mRNA transcription dependency, and
GR and MR occupancy are strikingly similar to those of
Fig. 11. Effects of CS or DHCS on Na,K-
ATPase a1- and b1-mRNA accumulation in rat
aortae. Bilaterally adrenalectomyzed rats were
subcutaneously treated with CS, DHCS, or
vehicle for 12 hours. (A) Northern blot
analyses. (B) Quantitations of the Northern
blot. Data are expressed as a relative increase
in mRNA expression compared with control
samples. The number of control, CS- or DHCS-
treated rats is 5. *P , 0.001 compared with
control.
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CS. Furthermore, the effects of DHCS on Na,K-ATPase
a1- and b1-subunit protein accumulation and Na,K-AT-
Pase activity are quite similar to those of CS. Accordingly,
the mechanisms for CS- and DHCS-induced a1- and
b1-mRNA accumulation are rather similar. Furthermore,
the 11bOHSD inhibitor carbenoxolone completely inhib-
ited the DHCS-induced an up-regulation of a1- and b1-
mRNA, whereas it caused no effect on the CS-induced
up-regulation of a1- or b1-mRNA. These data indicate that
the CS-induced up-regulation of a1- and b1-mRNA occurs
independently of 11bOHSD, whereas the DHCS-induced
upregulation of a1- and b1-mRNA occurs through
11bOHSD-dependent mechanisms. Recently, at least two
distinct isoforms of 11bOHSD have been identified:
11bOHSD-1, originally purified from liver [48], and
11bOHSD-2, characterized in kidney and placenta [49, 50].
The isoform 11bOHSD-2 is high-affinity, NAD-dependent,
exclusively 11b-dehydrogenase [50, 51], whose expression is
restricted to mineralocorticoid target tissues, placenta, and
a limited number of other tissues. By contrast, 11bOHSD-1
is widely distributed, with the highest levels in liver and
proximal tubules of the kidney as well as in tissues that also
express high levels of GR [21], including VSMC [25, 26,
52]. 11bOHSD-1, which has a lower affinity for steroid
substrate (Km, 2 mM for CS) than the type 2 isoform, is
NADP(H)-dependent, and is bidirectional in tissue homog-
enates and in purified microsomal fractions [48]. Reaction
direction has been proposed to reflect cosubstrate
(NADP1/NADPH) ratios, with NADP1 favoring 11b-de-
hydrogenase activity (conversion of CS to DHCS), and
NADPH favoring 11b-reductase activity (conversion of
DHCS to CS) [53]. pH has also been implicated in the
control of direction [54, 55]. A recent study demonstrated
that in vascular tissues the conversion of CS to DHCS
(dehydrogenase activity) was low relative to that in renal
cortex, even when the dehydrogenase was “driven” by the
addition of NADP1 [26]. In the present study, treatment
with carbenoxolone failed to magnify CS-mediated a1- and
b1-mRNA induction. These two studies suggest that in
vascular tissues 11b-reductase activity may predominate,
although it also has 11b-dehydrogenase activity [26, 52]. In
some tissues (such as, liver and skin fibroblasts), 11bOHSD
also catalyzes not only the 11b-dehydrogenase conversion
of cortisol to cortisone (or CS to DHCS), but also the
reverse 11b-reductase reactions, which are also inhibited by
carbenoxolone. For example, in TBM cells transfected with
rat liver 11bOHSD, exogenous DHCS is converted to CS
[54]. In primary cultures of rat hepatocytes, 11bOHSD is
also an exclusive 11b-reductase [55]. In human skin fibro-
blasts 11b-reductase activity is 5- to 10-fold greater than
11b-dehydrogenase activity [56]. Experiments that are
more representative of the in vivo state suggest that in
glucocorticoid target organs such as the liver, the activity is
predominantly reductase, since there is avid conversion of
oral cortisone to cortisol in humans [24]. Based on the
above findings and reports, we conclude that in VSMC
11bOHSD does not act as a barrier to glucocorticoid
access; rather, the enzyme stimulates conversion of inactive
DHCS into active CS and thus modulates Na,K-ATPase
gene regulation. It has been proposed that in glucocorticoid
target organs, 11bOHSD could act to maintain high local
cortisol or CS concentrations, thus ensuring adequate
exposure of GR [26, 55]. The role of 11bOHSD in the
regulation of vascular Na,K-ATPase needs to be more
clearly established.
In conclusion, we clearly demonstrated regulation of
Na,K-ATPase gene expression by CS and its metabolite,
DHCS, in VSMC and aortae. This may be involved in the
maintenance of normal blood pressure as well as in the
pathophysiology of glucocorticoid-induced hypertension.
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APPENDIX
Abbreviations used in this article are: ADP, adenosine 59-diphosphate;
ADX, adrenalectomized; ATP, adenosine triphosphate; 11BOHSD, 11B-
hydroxysteroid dehydrogenase; CS, corticosterone; DC, 21-desoxycorti-
sone; DHCS, 11-dehydrocorticosterone; FBS, fetal bovine serum;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GR, type II glu-
cocorticoid receptor; MEM, Eagle’s minimal essential medium; MR,
mineralocorticoid receptor; PBS, phosphate buffered saline; RU38486,
glucorticoid receptor antagonist; SDS-PAGE, sodium dodecyl sulfate-
polyarylamide gel electrophoresis; SSC, standard saline citrate; TBS-
Tween, Tris buffered saline-Tween 20; VSMC, vascular smooth muscle
cells; ZK91587, mineralocorticoid receptor antagonist.
REFERENCES
1. FLEMING WW: The electrogenic Na1, K1-pump in smooth muscle:
Physiologic and pharmacologic significance. Ann Rev Pharmacol Toxi-
col 20:129–149, 1980
2. SWEADNER KJ: Isozymes of the Na1-K1-ATPase. Biochim Biophys
Acta 988:185–220, 1989
3. HERRERA VL, EMANUEL JR, RUIZ-OPAZO N, LEVENSON R, NADAL-
GINARD B: Three differentially expressed Na,K-ATPase a subunit
isoforms: Structural and functional implications. J Cell Biol 105:1855–
1865, 1987
4. ORLOWSKI J, LINGREL JB: Tissue-specific and developmental regula-
tion of rat Na1-K1-ATPase catalytic a-isoform and b-subunit mR-
NAs. J Biol Chem 263:10436–10442, 1988
5. SCHULL GE, GREEB J, LINGREL JB: Molecular cloning of three distinct
forms of the Na1-K1-ATPase a-subunit from rat brain. Biochemistry
25:8125–8123, 1986
Muto et al: Na,K-ATPase gene expression by glucocorticoids506
6. GLOOR S, ANTONICEK H, SWEADNER KJ, PAGLIUSI S, FRANK R, MOOS
M, SCHAUCHNER M: The adhesion molecule on glia (AMOG) is a
homologous of the beta subunit of the Na,K-ATPase. J Cell Biol
110:165–170, 1990
7. MARTIN-VASALLO P, DACKOWSKI W, EMANUEL JR, LEVENSON R:
Identification of a putative isoform of the Na,K-ATPase b subunit.
Primary structure and tissue-specific expression. J Biol Chem 264:
4613–4618, 1989
8. MALIK N, CANFIELD VA, BECKERS MC, GROS P, LEVENSON R:
Identification of the mammalian Na,K-ATPase b subunit. J Biol Chem
271:22754–22758, 1996
9. OGUCHI A, IKEDA U, KANBE T, TSURUYA Y, YAMAMOTO K,
KAWAKAMI K, MEDFORD RM, SHIMADA K: Regulation of Na-K-
ATPase gene expression by aldosterone in vascular smooth muscle
cells. Am J Physiol 265:H1167–H1172, 1993
10. YAMAMOTO K, IKEDA U, OKADA K, SAITO T, KAWAKAMI K, SHIMADA
K: Sodium ion mediated regulation of Na/K-ATPase gene expression
in vascular smooth muscle cells. Cardiovasc Res 28:957–962, 1994
11. EL MERNISSI G, DOUCET A: Short-term effects of aldosterone and
dexamethasone on Na-K-ATPase along the rabbit nephron. Pflu¨gers
Arch 399:147–151, 1983
12. MUTO, S: Action of aldosterone on renal collecting tubule cells. Curr
Opinion Nephrol Hypertens 4:31–40, 1995
13. NARAY-FEJES-TOTH A, FEJES-TOTH G: Glucocorticoid receptors me-
diate mineralocorticoid-like effects in cultured collecting duct cells.
Am J Physiol 259:F672–F678, 1990
14. WALKER BR, YAN JL, BRETT LP, SECKL JR, MONDER C, WILLIAMS
BC, EDWARDS CRW: 11b-hydroxysteroid dehydrogenase in vascular
smooth muscle and heart: Implications for cardiovascular responses to
glucocorticoids. Endocrinol 129:3305–3312, 1991
15. WANG Z-M, YASUI M, CELSI G: Glucocorticoids regulate the tran-
scription of Na1-K1-ATPase genes in the infant rat kidney. Am J
Physiol 267:C450–C455, 1994
16. TURNAMIAN SG, BINDER HJ: Regulation of active sodium and potas-
sium transport in the distal colon of the rat. Role of the aldosterone
and glucocorticoid receptors. J Clin Invest 84:1924–1929, 1989
17. TODD-TURLA K, SCHNERMANN J, FEJES-TOTH G, NARAY-FEJES-TOTH
A, SMITH A, KILLEN PD, BRIGGS J: Distribution of mineralocorticoid
and glucocorticoid receptor mRNA along the nephron. Am J Physiol
264:F781–F791, 1993
18. GRUNFELD J-P, ELOY L, MOURA A-M, GANEVAL D, RAMOS-FRENDO
B, WORCEL M: Effects of antiglucocorticoids on glucocorticoid hyper-
tension in the rat. Hypertension 7:292–299, 1984
19. MEYER WJ, NICHOLS NR: Mineralocorticoid binding in cultured
smooth muscle cells and fibroblasts from rat aorta. J Steroid Biochem
14:1157–1168, 1981
20. MUTO S, NEMOTO J, OHTAKA A, WATANABE Y, YAMAKI M,
KAWAKAMI K, NAGANO K, ASANO Y: Differential regulation of
Na1-K1-ATPase gene expression by corticosteroids in vascular
smooth muscle cells. Am J Physiol 270:C731–C739, 1996
21. SECKL JR: 11b-hydroxysteroid dehydrogenase isoforms and their
implication for blood pressure regulation. Eur J Clin Invest 23:589–
601, 1993
22. STEWART PM, CORRIE JET, SHACKLETON CHL, EDWARDS CRW:
Syndrome of apparent mineralocorticoid excess: A defect in the
cortisol-cortisone shuttle. J Clin Invest 82:340–349, 1988
23. STEWART PM, WALLACE AM, VALENTINO R, BURT D, SHACKLETON
CHL, EDWARDS CRW: Mineralocorticoid activity of liquorice: 11b-
hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2:821–
824, 1987
24. STEWART PM, WALLACE AM, ATHERDEN SM, SHEARING CH, ED-
WARDS CRW: Mineralocorticoid activity of carbenoxolone: Contrast-
ing effects of carbenoxolone and liquorice on 11b-hydroxysteroid
dehydrogenase activity in man. Clin Sci 78:49–54, 1990
25. KORNEL L: Colocalization of 11b-hydroxysteroid dehydrogenase and
mineralocorticoid receptors in cultured vascular smooth muscle cells.
Am J Hypertens 7:100–103, 1994
26. VERREY F, SCHAERER E, ZOERKLER P, PACCOLAT MP, GEERING K,
KRAEHENBUHL JP, ROSSIER BC: Regulation by aldosterone of
Na1,K1-ATPase mRNAs, protein synthesis, and sodium transport in
cultured kidney cells. J Cell Physiol 104:1231–1237, 1987
27. BONDY PK: The adrenal cortex, in Duncan’s Disease of Metabolism
(7th ed), edited by BONDY PK, ROSENBERG LE, Philadelphia, WB
Saunders Co., 1974, p 1115
28. HARA Y, URAYAMA O, KAWAKAMI K, NOJIMA H, KOJIMA T, OHTA T,
NAGANO K, NAKAO M: Primary structures of two types of alpha-
subunit of rat brain Na1-K1-ATPase deduced from cDNA sequences.
J Biochem 102:43–58, 1987
29. YOUNG RM, SHULL GE, LINGREL JB: Multiple mRNAs from rat
kidneys and brain encoding a single Na1, K1-ATPase b subunit
protein. J Biol Chem 262:4905–4110, 1987
30. GARG LC, SAHA PK, MOHUCZY-DOMINIAK D: Cholinergic inhibition
of Na-K-ATPase via activation of protein kinase C in Madin-Darby
canine kidney cells. J Am Soc Nephrol 4:195–205, 1993
31. MCDONOUGH AA, MAGYAR CE, KOMATSU Y: Expression of Na1-K1-
ATPase a- and b-subunits along rat nephron: isoform specificity and
response to hypokalemia. Am J Physiol 267:C901–C908, 1994
32. NEMOTO J, MUTO S, OHTAKA A, KAWAKAMI K, ASANO Y: Serum
transcriptionally regulates Na1-K1-ATPase gene expression in vascu-
lar smooth muscle cells. Am J Physiol 273:C1088–C1099, 1997
33. SKOU JC: Further investigations on a Mg111Na1-activated adeno-
sinetriphosphatase, possibly related to the active, linked transport of
Na1 and K1 across the nerve membrane. Biochim Biophys Acta
42:6–23, 1960
34. SCHONER W, VON ILBERG C, KRAMER R, SEUBERT W: On the
mechanism of Na1- and K1-stimulated hydrolysis of adenosine
triphophate. 1. Purification and properties of a Na1- and K1-activated
ATPase from ox brain. Eur J Biochem 1:334–343, 1967
35. MARTIN RS, JONES WJ, HASLETT JP: Animal model to study the
effects of adrenal hormones on epithelial function. Kidney Int 24:386–
391, 1983
36. BREM AS, BINA RB, KING T, MORRIS DJ: Bidirectional activity of
11b-hydroxysteroid dehydrogenase in vascular smooth muscle cells.
Steroids 60:406–410, 1995
37. BUJALSKA I, SHIMOJO M, HOWIE A, STEWART P: Human 11b-hydrox-
ysteroid dehydrogenase: studies on the stably transfected isoforms and
localization of the type 2 isozyme within renal tissue. Steroids 77:77–
82, 1997
38. ROVNER AS, MURPHY RA, OWENS GK: Expression of smooth muscle
and nonmuscle myosin heavy chain in cultured vascular smooth
muscle cells. J Biol Chem 261:14740–14745, 1986
39. OHARA T, IKEDA U, MUTO S, OGUCHI A, TSURUYA Y, YAMAMOTO K,
KAWAKAMI K, SHIMADA K, ASANO Y: Thyroid hormone stimulates
Na1-K1-ATPase gene expression in cultured rat mesangial cells. Am J
Physiol 265:F370–F376, 1993
40. BHUTADA A, WASSYNGER WW, ISMAIL-BEIGI F: Dexamethasone
markedly induces Na,K-ATPase mRNAb1 in a rat liver cell line. J Biol
Chem 266:10859–10866, 1991
41. DANI C, BLANCHARD JM, DIECHACZYK ME, SABOUTY S, MARTY L,
HEANTEUR P: Extreme instability of myc mRNA in normal and
transformed human cells. Proc Natl Acad Sci USA 81:7046–7050, 1994
42. LEE W-S, HARDER JA, YOSHIZUMI M, LEE M-E, HABER E: Proges-
terone inhibits arterial smooth muscle cell proliferation. Nature Med
3:1005–1008, 1997
43. DUNCAN RL, GROGAN, WM, KRAMER LB, WATLINGTON CO: Corti-
costerone’s metabolite is an agonist for Na1 transport stimulation in
A6 cells. Am J Physiol 255:F736–F748, 1988
44. HAYASHI T, KORNEL L: Cortisol-21-sulfate (FS) is a specific ligand for
intracellular transcortin: Demonstration of three types of high affinity
corticosteroid binders in bovine aortic cytosol by a combined use of FS
and RU 28362. Endocrinol 126:307–316, 1990
45. HUSTED RF, LAPLACE JR, STOKES JB: Enhancement of electrogenic
Na transport across rat inner medullary collecting duct by glucocor-
ticoid and by mineralocorticoid hormones. J Clin Invest 86:498–506,
1990
46. TSUGANEZAWA H, HAYASHI M, FUJII Y, YAMAJI Y, IYORI M, SARUTA
T: Corticosterone increases Na,K-ATPase activity in rat cortical
collecting ducts with inhibition of 11b-hydroxysteroid dehydrogenase.
Renal Physiol Biochem 18:66–72, 1995
47. FULLER PJ, VERITY K: Colonic sodium-potassium adenosine triphos-
phate subunit gene expression: Ontogeny and regulation by adreno-
cortical steroids. Endocrinol 127:32–38, 1990
48. LAKSHMI V, MONDER C: Purification and characterization of the corti-
costeroid 11b-dehydrogenase components of the rat liver 11b-hydroxys-
teroid dehydrogenase complex. Endocrinol 123:2390–2398, 1988
Muto et al: Na,K-ATPase gene expression by glucocorticoids 507
49. BROWN RW, CHAPMAN KE, EDWARDS CRW, SECKL JR: Human
placental 11b-hydroxysteroid dehydrogenase: Partial purification and
evidence for a distinct NAD-dependent isoform. Endocrinol 132:
2614–2621, 1993
50. RUSVAI E, NARAY-FEJES-TOTH A: A new isoform of 11b-hydroxys-
teroid dehydrogenase in aldosterone target cells. J Biol Chem 268:
10717–10720, 1993
51. ALBISTON AL, OBEYESEKERE VR, SMITH RE, KROZOWSKI ZS: Cloning
and tissue distribution of the human 11b-hydroxysteroid dehydroge-
nase type 2 enzyme. Mol Cell Endocrinol 105:R11–R17, 1994
52. TAKEDA Y, MIYAMORI I, YONEDA T, ITO Y, TAKEDA R: Expression of
11b-hydroxysteroid dehydrogenase mRNA in rat vascular smooth
muscle cells. Life Sci 54:281–285, 1993
53. MONDER C, SHACKLETON CHL: 11b-hydroxysteroid dehydrogenase:
Fact or fancy? Steroids 44:383–415, 1984
54. DUPERREX H, KENOUCH S, GAEGGELER HP, SECKL JR, EDWARDS
CRW, FARMAN N, ROSSIER BC: Rat 11b-hydroxysteroid dehydroge-
nase complementary deoxyribonucleic acid encodes oxoreductase
activity in a mineralocorticoid-responsive toad bladder cell line.
Endocrinol 132:612–619, 1993
55. JAMIESON PM, CHAPMAN KE, EDWARDS CRW, SECKL JR: 11b-
hydroxysteroid dehydrogenase is an exclusive 11b-reductase in pri-
mary cultures of rat hepatocytes: Effects of physiological and hor-
monal manipulations. Endocrinol 136:4754–4761, 1995
56. HAMMAMI MM, SIITERI PK: Regulation of 11b-hydroxysteroid dehy-
drogenase activity in human skin fibroblasts: Enzymatic modulation of
glucocorticoid action. J Clin Endocrinol 73:326–334, 1991
Muto et al: Na,K-ATPase gene expression by glucocorticoids508
